Healthcare Today Montana
SEE OTHER BRANDS

News on health and wellness in Montana

Healthcare Today Montana: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Healthcare Today Montana.

Press releases published on August 13, 2025

Vireo Growth Inc. Announces Second Quarter 2025 Results

Vireo Growth Inc. Announces Second Quarter 2025 Results

– Q2 GAAP revenue of $48.1 million increased 91% year-over-year, driven by recently-closed merger transactions – – Q2 pro forma financial results were in line with management’s previously communicated expectations – – Recent $153 million refinancing …

X4 Pharmaceuticals Announces Closing of Upsized $85 Million Private Placement

X4 Pharmaceuticals Announces Closing of Upsized $85 Million Private Placement

BOSTON, Aug. 13, 2025 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today closed an upsized private placement of 11,040,776 shares of common stock and pre- …

BiomX Reports Second Quarter 2025 Financial Results and Provides Program Updates

BiomX Reports Second Quarter 2025 Financial Results and Provides Program Updates

Positive Phase 2 results for BX211 demonstrated >40% wound size reduction vs. placebo in diabetic foot osteomyelitis patients; Planning underway for potential registrational study Nature Communications publication of new BX004 Phase 1b/2a data demonstrated …

Ocugen, Inc. Announces Positive Scientific Advice from the European Medicines Agency Related to the Approval Pathway for OCU410ST—Modifier Gene Therapy for Stargardt Disease

Ocugen, Inc. Announces Positive Scientific Advice from the European Medicines Agency Related to the Approval Pathway for OCU410ST—Modifier Gene Therapy for Stargardt Disease

MALVERN, Pa., Aug. 13, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that the Committee for Medicinal Products for Human Use (CHMP) …

Neuronascent Announces Progress for Lead Candidate NNI-362: Publication of Phase 1a Clinical Trial Results and FDA Grants Waiver of Fee for Canine Cognitive Disorder 2025 Submissions

Neuronascent Announces Progress for Lead Candidate NNI-362: Publication of Phase 1a Clinical Trial Results and FDA Grants Waiver of Fee for Canine Cognitive Disorder 2025 Submissions

BALTIMORE., Aug. 13, 2025 (GLOBE NEWSWIRE) -- Neuronascent Inc., a privately-held neuron regeneration therapeutics company, today announced that the Phase 1a trial in aged human subjects of its NNI-362 therapy was published in Alzheimer’s Research and …

Instil Bio Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Instil Bio Reports Second Quarter 2025 Financial Results and Provides Corporate Update

With the clearance of the U.S. IND, initiation of the U.S. clinical trial of AXN-2510/IMM2510 (“‘2510”) anticipated before the end of 2025 Updated ‘2510 monotherapy data in squamous-NSCLC to be presented at IASLC’s 2025 World Conference on Lung Cancer ( …

Scilex Holding Company (Nasdaq: SCLX) Announces Effectiveness of Registration Statement on Form S-4 for the Proposed Business Combination of Denali Capital Acquisition Corp. and Semnur Pharmaceuticals, Inc., a Majority-Owned Subsidiary of Scilex

Scilex Holding Company (Nasdaq: SCLX) Announces Effectiveness of Registration Statement on Form S-4 for the Proposed Business Combination of Denali Capital Acquisition Corp. and Semnur Pharmaceuticals, Inc., a Majority-Owned Subsidiary of Scilex

Denali’s registration statement on Form S-4 declared effective by the Securities and Exchange Commission Extraordinary general meeting of Denali Capital Acquisition Corp. shareholders to approve the proposed business combination is scheduled to be held on …

Greenwich LifeSciences Announces Expansion of Flamingo-01 into Romania

Greenwich LifeSciences Announces Expansion of Flamingo-01 into Romania

STAFFORD, Texas, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-100, an immunotherapy …

LIO Launches Next-Generation Inpatient Mental Health Platform with Advanced Rounding, Monitoring, and Compliance Tools

LIO Launches Next-Generation Inpatient Mental Health Platform with Advanced Rounding, Monitoring, and Compliance Tools

WILMINGTON, Del., Aug. 13, 2025 (GLOBE NEWSWIRE) -- LIO today announced the launch of its new all-in-one platform for inpatient mental health services, featuring a compliance reporting suite, next generation digital observations, and adaptive monitoring …

Corza Medical Launches Biomedical Textiles Innovation Lab to Accelerate OEM Product Development

Corza Medical Launches Biomedical Textiles Innovation Lab to Accelerate OEM Product Development

TAUNTON, U.K., Aug. 13, 2025 (GLOBE NEWSWIRE) -- Corza Medical, a leading global manufacturer of surgical technologies and medical device components announced today the launch of its Biomedical Textiles Innovation Lab, a state-of-the-art facility designed …

Greywolf Therapeutics begins dosing of the first treatment to target the antigenic source of autoimmunity

Greywolf Therapeutics begins dosing of the first treatment to target the antigenic source of autoimmunity

This is the first ever autoimmunity study to evaluate a potential functional cure that targets the antigenic source – the origin of autoimmune disease The Phase 1/2 study (up to 141 participants) will evaluate the safety, tolerability and efficacy of …

Santhera schließt Vereinbarung mit GEN über den Vertrieb von AGAMREE® (Vamorolon) in der Türkei

Santhera schließt Vereinbarung mit GEN über den Vertrieb von AGAMREE® (Vamorolon) in der Türkei

Pratteln, Schweiz, 13. August 2025 – Santhera Pharmaceuticals (SIX: SANN) gibt die Unterzeichnung einer exklusiven Vereinbarung mit Gen İlaç ve Sağlık Ürünleri San. ve Tic. A.Ş. (GEN) über den Vertrieb und die Vermarktung von AGAMREE® (Vamorolon) in der …

  Santhera Secures Agreement with GEN for the Distribution of AGAMREE® (Vamorolone) in Türkiye

Santhera Secures Agreement with GEN for the Distribution of AGAMREE® (Vamorolone) in Türkiye

Pratteln, Switzerland, 13 August, 2025 – Santhera Pharmaceuticals (SIX: SANN) announces the signing of an exclusive agreement with Gen İlaç ve Sağlık Ürünleri San. ve Tic. A.Ş. (GEN) for the distribution and promotion of AGAMREE® (vamorolone) in Türkiye …

Compass Therapeutics Announces Pricing of Upsized $120 Million Public Offering

Compass Therapeutics Announces Pricing of Upsized $120 Million Public Offering

BOSTON, Aug. 12, 2025 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (“Compass”) (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today …

Global High-Throughput Screening Market to Surpass USD 50.2 Billion by 2029 | MarketsandMarkets™.

Global High-Throughput Screening Market to Surpass USD 50.2 Billion by 2029 | MarketsandMarkets™.

Delray Beach, FL, Aug. 12, 2025 (GLOBE NEWSWIRE) -- North America Leads Today, Asia Pacific to Record Fastest Growth The global high throughput screening market, valued at US$25.7 billion in 2023, stood at US$28.8 billion in 2024 and is projected to …

Share us

on your social networks:
AGPs

Get the latest news on this topic.

SIGN UP FOR FREE TODAY

No Thanks

By signing to this email alert, you
agree to our Terms & Conditions